Japan Lifeline Co., Ltd.
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/10/01Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2023/01/31 | ¥29.01 | ¥11.20 | -61.4% |
| 2022/07/28 | ¥21.27 | ¥24.73 | +16.3% |
| 2022/05/11 | ¥26.28 | ¥24.44 | -7.0% |
| 2022/01/28 | ¥30.90 | ¥24.02 | -22.3% |
Shareholder Composition
Updated 2026/10/01Dividend History 3Years Growth
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥79 | +49.1% |
| 2025 | ¥53 | +26.2% |
| 2024 | ¥42 | +10.5% |
| 2023 | ¥38 | 0.0% |
| 2022 | ¥38 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥51,469M | ¥51,750M | ¥51,384M | ¥56,610M |
| Gross Profit | ¥28,835M | ¥29,895M | ¥30,986M | ¥34,191M |
| Operating Income | ¥9,981M | ¥10,844M | ¥10,899M | ¥12,336M |
| Pretax Income | ¥10,117M | ¥9,823M | ¥10,601M | ¥12,060M |
| Net Income | ¥7,484M | ¥6,891M | ¥7,515M | ¥9,317M |
| EPS | ¥93.13 | ¥88.22 | ¥98.73 | ¥131.43 |
| Operating Margin | 19.39% | 20.95% | 21.21% | 21.79% |
| Balance Sheet | ||||
| Total Assets | ¥73,197M | ¥74,641M | ¥73,509M | ¥75,123M |
| Total Equity | ¥54,567M | ¥56,196M | ¥58,101M | ¥59,913M |
| Total Liabilities | ¥18,630M | ¥18,445M | ¥15,408M | ¥15,210M |
| Cash | ¥16,058M | ¥18,357M | ¥12,669M | ¥11,014M |
| Interest-bearing Debt | ¥8,141M | ¥6,685M | ¥4,489M | ¥3,833M |
| Equity Ratio | 74.55% | 75.29% | 79.04% | 79.75% |
| D/E Ratio | 0.15 | 0.12 | 0.08 | 0.06 |
| Cash Flow | ||||
| Operating CF | ¥10,246M | ¥11,201M | ¥6,918M | ¥9,113M |
| Investing CF | -¥1,131M | -¥2,461M | -¥4,056M | -¥1,801M |
| Financing CF | -¥6,804M | -¥6,476M | -¥8,553M | -¥9,040M |
| Free CF | ¥8,388M | ¥9,472M | ¥4,578M | ¥7,514M |
| Efficiency | ||||
| ROE | 13.72% | 12.26% | 12.93% | 15.55% |
| ROA | 10.22% | 9.23% | 10.22% | 12.40% |
Latest IR Information
-
Notice Regarding Transfer of a Specific Subsidiary Associated with the Acquisition of U.S. Cross Vascular, Inc. and Capital Injection
Japan Lifeline Co., Ltd. will acquire all shares of Cross Vascular, Inc. through JLL Med USA and make an additional capital injection into the company. Number of shares acquired: 8,900,000 shares; purchase price: approx. 977 million yen; JLL Med USA...
Read more -
Notice of Transfer of a Specific Subsidiary Associated with Capital Increase for US Subsidiary
Capital increase to US subsidiary JLL Med USA was executed. Increase amount: 10.0 million USD; post-increase capital: 10.4 million USD; equity ownership: 100% and classification as a wholly owned subsidiary. The impact on consolidated results for the fiscal year ending...
Read more -
【Japan Lifeline】Revised Interim Dividend and Special Dividend｜July 2026
Japan Lifeline has revised its dividend forecast for the fiscal year ending March 2027 and has decided to implement a special dividend of 25 yen per share. This is expected to lead to changes in total dividends and shareholder returns.
Read more -
Japan Lifeline Q1 Earnings for FY2027｜Sales of ¥15.9 billion (up 8.8% YoY)
Japan Lifeline achieved sales of ¥15.9 billion (up 8.8% YoY) in the first quarter of FY2027, with net profit of ¥230 million (almost flat). The company recorded record highs driven by new products and overseas expansion, despite a decrease in...
Read more -
[Japan Lifeline] Share Buyback and Shareholder Return Measures | July 2026
Japan Lifeline will dispose of 163,600 shares of treasury stock at 1,450 yen per share based on the performance-linked stock compensation system introduced in 2018, transferring approximately 237.22 million yen to trust accounts. The disposal is scheduled for August 20,...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,587
Rating Score: 2.67 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Japan Lifeline Co., Ltd., a medical device company, engages in manufacturing and sale of medical device in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, disposable ECG recorder, and venous vascular closure system. Its cardiovascular and endografting products consist of vascular and open stent grafts, and abdominal stent-grafts. In addition, the company offers gastrointestinal intervention products, including cholangioscope, biliary tube stent, papillary balloon dilatation catheter, self-expandable duodenal and colonic stent, endoscopic guidewire, and radiofrequency ablation systems; structural heart disease intervention products, such as radiofrequency wires and atrial septal defect closure devices; and embolic coil and aspiration catheter products. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.
